Proteomic risk scores can help identify high-risk patients and monitor short- and long-term effects of treatment
Proteomic risk scores can help identify high-risk patients and monitor short- and long-term effects of treatment
A webinar presented by Clare Paterson, PhD, Associate Director of Clinical Research, SomaLogic, and Jessica Chadwick, PhD, Scientist, SomaLogic
Abstract
In this 1-hour discussion, you will learn how large-scale proteomics can be leveraged for multiple applications in the field of oncology. The focus will be on two new avenues of oncology research. The first is using proteomic risk scores to monitor the cardiotoxic effects of anthracycline treatment and identify patients who may benefit from cardioprotective therapy. The other is developing blood-based protein tests for stratifying lung cancer susceptibility. From biomarker discovery to medicine application and the potential to inform and impact patients’ standard of care—there is a lot to learn and look forward to in oncology research using proteomics.
Clare Paterson, PhD
Associate Director of Clinical Research, SomaLogic
Prior to SomaLogic, Dr. Paterson conducted a fellowship in the clinical brain disorders branch at the National Institutes of Health (NIH) before becoming an Assistant Professor in Psychiatry at the University of Colorado School of Medicine.
Her academic research career focused on the use of -omics technologies to map how the human brain develops and ages and is altered in psychiatric illnesses, with the aim of ultimately uncovering new means of patient stratification and treatment discovery.
Jessica Chadwick, PhD
Scientist, SomaLogic
Dr. Jessica Chadwick is a scientist in the Clinical Research & Development department at SomaLogic. She completed her PhD in biochemistry at The Ohio State University as an NIH fellow. Her academic research focused on novel therapeutic strategies for treating Duchenne muscular dystrophy.
Dr. Chadwick has worked at SomaLogic for over 5 years on the development and productization of proteomic-based cardiometabolic tests. More recently she led an exciting new body of work aimed at assessing the robustness and sensitivity of these tests to interventions.
Protein biomarker models for oncology risk assessment and treatment monitoring
A webinar presented by Clare Paterson, MD, and Jessica Chadwick, MD
Contact us to learn more today
More webinars
WebinarOpening the black box: Building and evaluating machine learning models for proteomics
Machine learning can be a powerful way to extract multivariate signals from high-dimensional proteomics data, but only when models are built and evaluated with rigor. In this on-demand webinar, explore a practical framework for developing predictive and explanatory models, with an emphasis on study design choices that help prevent data leakage, reduce overfitting, and improve reproducibility.
WebinarBeyond the trees: See the bigger biological picture with pathway enrichment analysis
Proteomic data holds enormous potential—but the biology is rarely contained in a single protein. When you’re handed a list of differentially abundant proteins, the next challenge is turning that list into a clear, testable story about mechanisms and processes.
WebinarFinding the signal: Identifying reproducible biomarkers in high-plex proteomics
In biomarker discovery, the challenge is rarely a lack of data. Rather, it is knowing how to separate meaningful biological signal from technical distraction. This webinar focuses on how to use univariate analysis as a practical and powerful entry point for biomarker discovery in high-plex proteomics studies.